-+ 0.00%
-+ 0.00%
-+ 0.00%
Betta Pharmaceuticals (300558.SZ): Ensartinib hydrochloride capsules approved for marketing by the European Commission
Share
Listen to the news

Zhitong Financial App News, Betta Pharmaceutical (300558.SZ) issued an announcement. Recently, the marketing license application for ensartinib hydrochloride capsules (“ensartinib”) declared by the company's holding subsidiary Xdiscovery Holdings, Inc. (“Xdiscovery”) was approved by the European Commission (EC) (marketing license number: EU/1/26/2078) for “treatment of patients with anaplastic lymphoma kinase (ALK) -positive advanced non-small cell lung cancer (NSCLC).” Ensatinib became the first domestically produced ALK inhibitor approved for marketing in China, the US, and the European Union.

Ensatinib is the first domestically produced ALK inhibitor for which the company has independent intellectual property rights. It is also the first innovative drug targeting small molecule lung cancer to be marketed globally under the leadership of a Chinese company. Ensatinib has been approved for listing by the European Commission (EC), which is an important step forward in the company's continued global commercialization process of independent innovative drugs. Currently, the company is actively expanding the commercial layout of ensartinib in emerging markets to further enhance the global accessibility of independently innovative drugs.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending